- Home
- ITOS vs IMMP Comparison
ITOS vs IMMP Comparison
Compare ITOS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- IMMP
- Stock Information
- Founded
- ITOS 2011
- IMMP 1987
- Country
- ITOS United States
- IMMP Australia
- Employees
- ITOS N/A
- IMMP N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- ITOS Health Care
- IMMP Health Care
- Exchange
- ITOS Nasdaq
- IMMP Nasdaq
- Market Cap
- ITOS 271.1M
- IMMP 304.0M
- IPO Year
- ITOS 2020
- IMMP N/A
- Fundamental
- Price
- ITOS $7.41
- IMMP $2.04
- Analyst Decision
- ITOS Strong Buy
- IMMP Buy
- Analyst Count
- ITOS 3
- IMMP 2
- Target Price
- ITOS $21.33
- IMMP $8.50
- AVG Volume (30 Days)
- ITOS 512.7K
- IMMP 162.0K
- Earning Date
- ITOS 11-12-2024
- IMMP 01-03-2025
- Dividend Yield
- ITOS N/A
- IMMP N/A
- EPS Growth
- ITOS N/A
- IMMP N/A
- EPS
- ITOS N/A
- IMMP N/A
- Revenue
- ITOS $35,000,000.00
- IMMP $2,563,302.00
- Revenue This Year
- ITOS $271.18
- IMMP N/A
- Revenue Next Year
- ITOS N/A
- IMMP $10.84
- P/E Ratio
- ITOS N/A
- IMMP N/A
- Revenue Growth
- ITOS N/A
- IMMP 9.59
- 52 Week Low
- ITOS $7.09
- IMMP $1.66
- 52 Week High
- ITOS $18.75
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- ITOS 36.39
- IMMP 49.23
- Support Level
- ITOS $7.09
- IMMP $2.00
- Resistance Level
- ITOS $7.53
- IMMP $2.24
- Average True Range (ATR)
- ITOS 0.37
- IMMP 0.13
- MACD
- ITOS -0.02
- IMMP -0.02
- Stochastic Oscillator
- ITOS 21.28
- IMMP 22.22
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.